Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Advances in AI Platform Provide an Ability to Rapidly Predict, Identify and Design Biomolecular Structures to Accelerate the Pace and Reduce the Cost of Drug Discovery and Development

Publications

This is some text inside of a div block.

February 23, 2024

Media Contacts

Related announcements

View All

Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform

Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting